Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 3
Abstract
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection. Material and methods. Patients were randomized 1:2:2 to receive placebo, faldaprevir 120 mg q.d. (12 or 24 weeks) or faldaprevir 240 mg q.d. (12 weeks) all with PegIFN/RBV (24–48 weeks). Faldaprevir 120 mg for 12 weeks only (STARTVerso1 only) required early treatment success (ETS, HCV RNA < 25 IU/mL at week 4 and undetected at week 8). All faldaprevir-treated patients with ETS stopped PegIFN/RBV at week 24. Primary endpoint: sustained virologic response 12 weeks post-treatment (SVR12). Results. SVR12 rates were significantly higher for patients treated with faldaprevir 120 or 240 mg (72% and 73%, respectively) compared with placebo (50%); estimated differences (adjusted for trial, race, and genotype-1 subtype) faldaprevir 120 mg 24% (95% CI: 17–31%, P < 0.0001), faldaprevir 240 mg 23% (95% CI: 16–30%, P < 0.0001). Subgroup analyses consistently showed higher SVR12 rates for patients receiving faldaprevir compared with placebo. The incidence of adverse events (AEs) was similar in faldaprevir 120-mg and placebo groups and slightly higher in the faldaprevir 240-mg group. Serious Aes were reported in 6%, 7%, and 8% of patients in placebo, faldaprevir 120-mg, and faldaprevir 240-mg groups, respectively. Conclusion. Addition of faldaprevir to PegIFN/RBV increased SVR12 in patients with HCV genotype-1, and was well tolerated. Faldaprevir 120 mg is effective in the treatment of HCV genotype-1. ClinicalTrials.gov: NCT01343888 and NCT01297270.
Authors and Affiliations
Donald Jensen, Tarik Asselah, Douglas Dieterich, Graham Foster, Mark Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric Yoshida, Christophe Moreno, Denis Ouzan, Luis Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung Paik, David Wong, Edward Tam, Kelly Kaita, S. Feinman, Jerry Stern, Florian Voss, John-Paul Gallivan, Wulf Böcher, Peter Ferenci
Keywords
Related Articles
- EP ID EP78574
- DOI 10.5604/16652681.1198803
- Views 153
- Downloads 0
Right hepatic artery aneurysms in a child with Kawasaki disease: flow-preserving endovascular treatment
Do older patients utilize excess health care resources after liver transplantation?
Introduction. Liver transplantation is a highly effective treatment for end-stage liver disease. However, there is debate over the practice of liver transplantation in older recipients (age ≥ 60 years) given the relative...
Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy
[b]Introduction[/b]. Detection of hepatitis C virus (HCV) has been reported in extrahepatic sites such as peripheral blood mononuclear cells and platelets. Quantitation of HCV-RNA in platelets from patients under antivir...
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was...
Severe aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome in a patient with non-A-E hepatitis virus infection